BeOne Medicines的基礎血液學產品線在EHA 2026上引領B細胞癌症創新新時代

Friday, June 12, 2026 1 min read

Key Takeaway: BeOne Medicines is set to present its foundational blood product line at EHA 2026, focusing on innovative treatments for hematological malignancies. The event aims to showcase advancements in the field and highlight the company's contributions. Details about specific products or research findings were not disclosed in the article.